NA Breast Cancer Drugs Market - Industry Trends and Forecast to 2034

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	179 Pages	Data Bridge Market Research	October, 2023	DAABD18360477

Best Price Guarantee
Price	from $3,500
Length	179 Pages
Publisher	Data Bridge Market Research
Published Date	October, 2023
SKU	DAABD18360477

NA Breast Cancer Drugs Market - Industry Trends and Forecast to 2034

The North America breast cancer drugs market is expected to reach USD 21,400.33 million by 2030 from USD 10,238.79 million in 2022, growing at a CAGR of 9.8% during the forecast period of 2023 to 2030.
Market Segmentation
North America Breast Cancer Drugs Market, By Product Type (Medication, Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), Cancer Type (Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), Inflammatory Breast Cancer, Paget’s Disease of the Nipple, Angiosarcoma of the Breast, Phyllodes Tumors of the Breast, Non-Invasive (In-situ) Types of Breast Cancer, Ductal Carcinoma In Situ (DCIS), Lobular Carcinoma In Situ (LCIS), Metastatic Breast Cancer, and Others), Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Drug Type (Generic and Branded), Age Group (Geriatric and Adults), Route of Administration (Oral and Intravenous), End User (Hospitals, Specialty Clinics, Cancer Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030

Overview of North America Breast Cancer Drugs Market Dynamics

Driver
• Advancement in drugs associated with breast cancer treatment

Restraint

• Rising cost of drugs associated with cancer treatment

Opportunity

• Government initiatives and other funding sources for cancer research
Market Players

Some of the major market players operating in the North America breast cancer drugs market are:

• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• AstraZeneca
• Novartis AG
• Eli Lilly and Company
• Merck & Co., Inc.
• Sanofi
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Mylan N.V. (A Subsidiary of Viatris Inc.)
• Teva Pharmaceutical Industries Ltd.
• Kyowa Kirin Co., Ltd.
• MacroGenics, Inc.
• Gilead Sciences, Inc.
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.

1 Introduction: 1.1 Objectives Of The Study; 1.2 Market Definition; 1.3 Overview Of North America Breast Cancer Drugs Market; 1.4 Currency And Pricing; 1.5 Limitations; 1.6 Markets Covered
2 Market Segmentation: 2.1 Markets Covered; 2.2 Geographical Scope; 2.3 Years Considered For The Study; 2.4 Currency And Pricing; 2.5 Dbmr Tripod Data Validation Model; 2.6 Primary Interviews With Key Opinion Leaders; 2.7 Dbmr Market Position Grid; 2.8 Multivariate Modelling; 2.9 Product Type Lifeline Curve; 2.10 Market End User Coverage Grid; 2.11 Secondary Sources; 2.12 Assumptions
3 Executive Summary
4 Premium Insights: 4.1 Porter's Five Forces; 4.2 Pestel Analysis; 4.3 Epidemiology; 4.4 Pipeline Analysis
5 Regulations
6 Market Overview: 6.1 Drivers; 6.1.1 Advancement In Drugs Associated With Breast Cancer Treatment; 6.1.2 Increasing Incidence Of Breast Cancer Across Different Countries; 6.1.3 Increasing Development In The Field Of Targeted Therapy For Breast Cancer; 6.1.4 Increasing Usage Of Hormone Therapy In Breast Cancer Treatment; 6.1.5 Growing Number Of Screening Programs Related To Breast Cancer; 6.2 Restraints; 6.2.1 Rising Cost Of Drugs Associated With Cancer Treatment; 6.2.2 Adverse Side Effects And Compatibility Concerns; 6.3 Opportunities; 6.3.1 Government Initiatives And Other Funding Sources For Cancer Research; 6.3.2 Integration Of Artificial Intelligence (Ai) In Drug Development; 6.3.3 Usage Of Adjuvant Therapies; 6.4 Challenges; 6.4.1 Complications Associated With Chemotherapy; 6.4.2 Lack In Early Detection Of Breast Cancer
7 North America Breast Cancer Drugs Market, By Product Type: 7.1 Overview; 7.2 Medication; 7.2.1 Anastrozole (Arimidex); 7.2.2 Cyclophosphamide (Cytoxan); 7.2.3 Exemestane (Aromasin); 7.2.4 Letrozole (Femara); 7.2.5 Others; 7.3 Chemotherapy; 7.3.1 Fluorouracil; 7.3.2 Methotrexate; 7.3.3 Paclitaxel; 7.3.4 Epirubicin; 7.3.5 Docetaxel; 7.3.6 Others; 7.4 Radiation Therapy; 7.5 Targeted Therapy; 7.5.1 Pembrolizumab; 7.5.2 Olaparib; 7.5.3 Laprotrectinib; 7.5.4 Entrectinib; 7.5.5 Others; 7.6 Others
8 North America Breast Cancer Drugs Market, By Stages: 8.1 Overview; 8.2 Stage I; 8.3 Stage Ii; 8.4 Stage 0; 8.5 Stage Iii; 8.6 Stage Iv
9 North America Breast Cancer Drugs Market, By Drug Type: 9.1 Overview; 9.2 Branded; 9.3 Generic
10 North America Breast Cancer Drugs Market, By Age Group: 10.1 Overview; 10.2 Geriatric; 10.3 Adults
11 North America Breast Cancer Drugs Market, By Cancer Type: 11.1 Overview; 11.2 Invasive Ductal Carcinoma (Idc); 11.3 Invasive Lobular Carcinoma (Ilc); 11.4 Inflammatory Breast Cancer; 11.5 Paget’s Disease Of The Nipple; 11.6 Angiosarcoma Of The Breast; 11.7 Phyllodes Tumors Of The Breast; 11.8 Noninvasive (In-situ) Types Of Breast Cancer; 11.9 Ductal Carcinoma In Situ (Dcis); 11.10 Lobular Carcinom Ain Situ (Lcis); 11.11 Metastatic Breast Cancer; 11.12 Others
12 North America Breast Cancer Drugs Market, By Route Of Administration: 12.1 Overview; 12.2 Intravenous; 12.3 Oral
13 North America Breast Cancer Drugs Market, By End User: 13.1 Overview; 13.2 Hospitals; 13.3 Cancer Centers; 13.4 Specialty Clinics; 13.5 Others 14 North America Breast Cancer Drugs Market, By Distribution Channel; 14.1 Overview; 14.2 Hospital Pharmacy; 14.3 Retail Pharmacy; 14.4 Online Pharmacy
15 North America Breast Cancer Drugs Market, By Region: 15.1 Overview; 15.2 North America; 15.2.1 U.S.; 15.2.2 Canada; 15.2.3 Mexico
16 North America Breast Cancer Drugs Market: Company Landscape: 16.1 Company Share Analysis: North America
17 Swot Analysis
18 Company Profiles: 18.1 F. Hoffmann-la Roche Ltd; 18.1.1 Company Snapshot; 18.1.2 Revenue Analysis; 18.1.3 Comapany Share Analysis; 18.1.4 Product Portfolio; 18.1.5 Recent Developments; 18.2 Pfizer Inc.; 18.2.1 Company Snapshot; 18.2.2 Revenue Analysis; 18.2.3 Comapany Share Analysis; 18.2.4 Product Portfolio; 18.2.5 Recent Developments; 18.3 Astrazeneca; 18.3.1 Company Snapshot; 18.3.2 Revenue Analysis; 18.3.3 Comapany Share Analysis; 18.3.4 Product Portfolio; 18.3.5 Recent Development 18.4 Novartis Ag; 18.4.1 Company Snapshot; 18.4.2 Revenue Analysis; 18.4.3 Comapany Share Analysis; 18.4.4 Product Portfolio; 18.4.5 Recent Development; 18.5 Eli Lilly And Company; 18.5.1 Company Snapshot; 18.5.2 Revenue Analysis; 18.5.3 Comapany Share Analysis; 18.5.4 Product Portfolio; 18.5.5 Recent Developments; 18.6 Abbvie, Inc.; 18.6.1 Company Snapshot; 18.6.2 Revenue Analysis; 18.6.3 Product Portfolio; 18.6.4 Recent Development; 18.7 Bristol-myers Squibb Company; 18.7.1 Company Snapshot; 18.7.2 Revenue Analysis; 18.7.3 Product Portfolio; 18.7.4 Recent Development; 18.8 Eisai Co., Ltd; 18.8.1 Company Snapshot; 18.8.2 Revenue Analysis; 18.8.3 Product Portfolio; 18.8.4 Recent Development; 18.9 Kyowa Kirin Co., Ltd; 18.9.1 Company Snapshot; 18.9.2 Revenue Analysis; 18.9.3 Product Portfolio; 18.9.4 Recent Development; 18.10 Merck & Co., Inc.; 18.10.1 Company Snapshot; 18.10.2 Revenue Analysis; 18.10.3 Product Portfolio; 18.10.4 Recent Development 18.11 Macrogenics, Inc.; 18.11.1 Company Snapshot; 18.11.2 Revenue Analysis; 18.11.3 Product Portfolio; 18.11.4 Recent Development; 18.12 Sanofi; 18.12.1 Company Snapshot; 18.12.2 Revenue Analysis; 18.12.3 Product Portfolio; 18.12.4 Recent Developments; 18.13 Teva Pharmaceutical Industries Ltd; 18.13.1 Company Snapshot; 18.13.2 Revenue Analysis; 18.13.3 Product Portfolio; 18.13.4 Recent Development; 18.14 Viatris Inc; 18.14.1 Company Snapshot; 18.14.2 Revenue Analysis; 18.14.3 Product Portfolio; 18.14.4 Recent Development; 18.15 Gilead Sciences, Inc; 18.15.1 Company Snapshot; 18.15.2 Revenue Analysis; 18.15.3 Product Portfolio; 18.15.4 Recent Development; 18.16 Takeda Pharmaceutical Company Limited; 18.16.1 Company Snapshot; 18.16.2 Revenue Analysis; 18.16.3 Product Portfolio; 18.16.4 Recent Development
19 Questionnaire
20 Related Reports
List Of Tables: Table 1 North America Breast Cancer Drugs Market, Pipeline Analysis; Table 2 North America Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 3 North America Medication In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 4 North America Medication In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 5 North America Chemotherapy In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 6 North America Chemotherapy In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 7 North America Radiation Therapy In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 8 North America Targeted Therapy In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 9 North America Targeted Therapy In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 10 North America Others In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 11 North America Breast Cancer Drugs Market, By Stages, 2022-2030 (Usd Million); Table 12 North America Stage I In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 13 North America Stage Ii In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 14 North America Stage 0 In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 15 North America Stage Iii In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 16 North America Stage Iv In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 17 North America Breast Cancer Drugs Market, By Drug Type, 2021-2030 (Usd Million); Table 18 North America Branded In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 19 North America Generic In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 20 North America Breast Cancer Drugs Market, By Age Group, 2021-2030 (Usd Million); Table 21 North America Geriatric In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 22 North America Adults In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 23 North America Breast Cancer Drugs Market, By Cancer Type, 2021-2030 (Usd Million); Table 24 North America Invasive Ductal Carcinoma (Idc) In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 25 North America Invasive Lobular Carcinoma (Ilc) In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 26 North America Inflammatory Breast Cancer In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 27 North America Paget’s Disease Of The Nipple In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 28 North America Angiosarcoma Of The Breast In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 29 North America Phyllodes Tumors Of The Breast In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 30 North America Noninvasive (In Situ) Types Of Breast Cancer In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 31 North America Ductal Carcinoma In Situ (Dcis) In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 32 North America Lobular Carcinoma In Situ (Lcis) In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 33 North America Metastatic Breast Cancer In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 34 North America Others In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 35 North America Breast Cancer Drugs Market, By Route Of Administration, 2021-2030 (Usd Million); Table 36 North America Intravenous In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 37 North America Oral In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 38 North America Breast Cancer Drugs Market, By End User, 2021-2030 (Usd Million); Table 39 North America Hospitals In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 40 North America Cancer Centers In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 41 North America Specialty Clinics In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 42 North America Others In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 43 North America Breast Cancer Drugs Market, By Distribution Channel, 2020-2030 (Usd Million); Table 44 North America Hospital Pharmacy In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 45 North America Retail Pharmacy In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 46 North America Online Pharmacy In Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 47 North America Breast Cancer Drugs Market, By Region, 2021-2030 (Usd Million); Table 48 North America Breast Cancer Drugs Market, By Country, 2021-2030 (Usd Million); Table 49 North America Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 50 North America Medication In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 51 North America Chemotherapy In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 52 North America Targeted Therapy In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 53 North America Breast Cancer Drugs Market, By Cancer Type, 2021-2030 (Usd Million); Table 54 North America Breast Cancer Drugs Market, By Stages, 2021-2030 (Usd Million); Table 55 North America Breast Cancer Drugs Market, By Drug Type, 2021-2030 (Usd Million); Table 56 North America Breast Cancer Drugs Market, By Age Group, 2021-2030 (Usd Million); Table 57 North America Breast Cancer Drugs Market, By Route Of Administration, 2021-2030 (Usd Million); Table 58 North America Breast Cancer Drugs Market, By End User, 2021-2030 (Usd Million); Table 59 North America Breast Cancer Drugs Market, By Distribution Channel, 2021-2030 (Usd Million); Table 60 U.S. Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 61 U.S. Medication In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 62 U.S. Chemotherapy In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 63 U.S. Targeted Therapy In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 64 U.S. Breast Cancer Drugs Market, By Cancer Type, 2021-2030 (Usd Million); Table 65 U.S. Breast Cancer Drugs Market, By Stages, 2021-2030 (Usd Million); Table 66 U.S. Breast Cancer Drugs Market, By Drug Type, 2021-2030 (Usd Million); Table 67 U.S. Breast Cancer Drugs Market, By Age Group, 2021-2030 (Usd Million); Table 68 U.S. Breast Cancer Drugs Market, By Route Of Administration, 2021-2030 (Usd Million); Table 69 U.S. Breast Cancer Drugs Market, By End User, 2021-2030 (Usd Million); Table 70 U.S. Breast Cancer Drugs Market, By Distribution Channel, 2021-2030 (Usd Million); Table 71 Canada Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 72 Canada Medication In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 73 Canada Chemotherapy In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 74 Canada Targeted Therapy In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 75 Canada Breast Cancer Drugs Market, By Cancer Type, 2021-2030 (Usd Million); Table 76 Canada Breast Cancer Drugs Market, By Stages, 2021-2030 (Usd Million); Table 77 Canada Breast Cancer Drugs Market, By Drug Type, 2021-2030 (Usd Million); Table 78 Canada Breast Cancer Drugs Market, By Age Group, 2021-2030 (Usd Million); Table 79 Canada Breast Cancer Drugs Market, By Route Of Administration, 2021-2030 (Usd Million); Table 80 Canada Breast Cancer Drugs Market, By End User, 2021-2030 (Usd Million); Table 81 Canada Breast Cancer Drugs Market, By Distribution Channel, 2021-2030 (Usd Million); Table 82 Mexico Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 83 Mexico Medication In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 84 Mexico Chemotherapy In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 85 Mexico Targeted Therapy In Breast Cancer Drugs Market, By Product Type, 2021-2030 (Usd Million); Table 86 Mexico Breast Cancer Drugs Market, By Cancer Type, 2021-2030 (Usd Million); Table 87 Mexico Breast Cancer Drugs Market, By Stages, 2021-2030 (Usd Million); Table 88 Mexico Breast Cancer Drugs Market, By Drug Type, 2021-2030 (Usd Million); Table 89 Mexico Breast Cancer Drugs Market, By Age Group, 2021-2030 (Usd Million); Table 90 Mexico Breast Cancer Drugs Market, By Route Of Administration, 2021-2030 (Usd Million); Table 91 Mexico Breast Cancer Drugs Market, By End User, 2021-2030 (Usd Million); Table 92 Mexico Breast Cancer Drugs Market, By Distribution Channel, 2021-2030 (Usd Million)
List Of Figures: Figure 1 North America Breast Cancer Drugs Market: Segmentation; Figure 2 North America Breast Cancer Drugs Market: Data Triangulation; Figure 3 North America Breast Cancer Drugs Market: Droc Analysis; Figure 4 North America Breast Cancer Drugs Market: North America Vs Regional Market Analysis; Figure 5 North America Breast Cancer Drugs Market: Company Research Analysis; Figure 6 North America Breast Cancer Drugs Market: Interview Demographics; Figure 7 North America Breast Cancer Drugs Market: Dbmr Market Position Grid; Figure 8 North America Breast Cancer Drugs Market: Market End User Coverage Grid; Figure 9 North America Breast Cancer Drugs Market: Segmentation; Figure 10 Rising Incidence Of Breast Cancer Is Driving The Growth Of North America Breast Cancer Drugs Market In The Forecast Period Of 2023 To 2030; Figure 11 Medication Segment Is Expected To Account For The Largest Share Of The North America Breast Cancer Drugs Market In 2023 & 2030; Figure 12 Drivers, Restraints, Opportunities, And Challenges Of North America Breast Cancer Drugs Market; Figure 13 North America Breast Cancer Drugs Market: By Product Type, 2022; Figure 14 North America Breast Cancer Drugs Market: By Product Type, 2023-2030 (Usd Million); Figure 15 North America Breast Cancer Drugs Market: By Product Type, Cagr (2023-2030); Figure 16 North America Breast Cancer Drugs Market: By Product Type, Lifeline Curve; Figure 17 North America Breast Cancer Drugs Market: By Stages , 2022; Figure 18 North America Breast Cancer Drugs Market: By Stages, 2023-2030 (Usd Million); Figure 19 North America Breast Cancer Drugs Market: By Stages, Cagr (2023-2030); Figure 20 North America Breast Cancer Drugs Market: By Stages, Lifeline Curve; Figure 21 North America Breast Cancer Drugs Market: By Drug Type, 2022; Figure 22 North America Breast Cancer Drugs Market: By Drug Type, 2023-2030 (Usd Million); Figure 23 North America Breast Cancer Drugs Market: By Drug Type, Cagr (2023-2030); Figure 24 North America Breast Cancer Drugs Market: By Drug Type, Lifeline Curve; Figure 25 North America Breast Cancer Drugs Market: By Age Group, 2022; Figure 26 North America Breast Cancer Drugs Market: By Age Group, 2023-2030 (Usd Million); Figure 27 North America Breast Cancer Drugs Market: By Age Group, Cagr (2023-2030); Figure 28 North America Breast Cancer Drugs Market: By Age Group, Lifeline Curve; Figure 29 North America Breast Cancer Drugs Market: By Cancer Type, 2022; Figure 30 North America Breast Cancer Drugs Market: By Cancer Type, 2023-2030 (Usd Million); Figure 31 North America Breast Cancer Drugs Market: By Cancer Type, Cagr (2023-2030); Figure 32 North America Breast Cancer Drugs Market: By T Cancer Type, Lifeline Curve; Figure 33 North America Breast Cancer Drugs Market: By Route Of Administration, 2022; Figure 34 North America Breast Cancer Drugs Market: By Route Of Administration, 2023-2030 (Usd Million); Figure 35 North America Breast Cancer Drugs Market: By Route Of Administration, Cagr (2023-2030); Figure 36 North America Breast Cancer Drugs Market: By Route Of Administration, Lifeline Curve; Figure 37 North America Breast Cancer Drugs Market: By End User, 2022; Figure 38 North America Breast Cancer Drugs Market: By End User, 2023-2030 (Usd Million); Figure 39 North America Breast Cancer Drugs Market: By End User, Cagr (2023-2030); Figure 40 North America Breast Cancer Drugs Market: By End User, Lifeline Curve; Figure 41 North America Breast Cancer Drugs Market: By Distribution Channel, 2022; Figure 42 North America Breast Cancer Drugs Market: By Distribution Channel, 2023-2030 (Usd Million); Figure 43 North America Breast Cancer Drugs Market: By Distribution Channel, Cagr (2023-2030); Figure 44 North America Breast Cancer Drugs Market: By Distribution Channel, Lifeline Curve; Figure 45 North America Breast Cancer Drugs Market: Snapshot (2022); Figure 46 North America Breast Cancer Drugs Market: Company Share 2022 (%)